MAFLD in Obese Children: A Challenging Definition

Overview

Journal Children (Basel)

Specialty Health Services

Date 2021 Apr 3

PMID 33806784

Citations 15

Authors

Anna Di Sessa

Stefano Guarino

Giuseppina Rosaria Umano

Mattia Arenella

Salvatore Alfiero

Gaetano Quaranta

Emanuele Miraglia Del Giudice

Pierluigi Marzuillo

Affiliations

Soon will be listed here.

Abstract

Background: Recently, the new definition of Metabolic (dysfunction) associated fatty liver disease (MAFLD) has gained remarkable scientific interest. We aimed to evaluate the effectiveness of MAFLD definition in selecting obese children at higher cardiovascular risk.

Methods: A total of 954 obese children and adolescents was retrospectively enrolled. Clinical, biochemical, and metabolic evaluations were performed. Hepatic steatosis was assessed by liver ultrasound. According to the metabolic status, the population was divided in three groups. Group 1 included obese patients without both non-alcoholic fatty liver disease (NAFLD) and metabolic dysregulation; group 2 included patients with obesity and NAFLD (then encompassing one MAFLD criterion); group 3 included patients with obesity, NAFLD and evidence of metabolic dysregulation (then encompassing more than 1 MAFLD criteria).

Results: Patients of Group 3 showed a worse cardiometabolic profile, as also proven by the higher percentage of prediabetes (defined as the presence of impaired fasting glucose or impaired glucose tolerance) compared to other groups ( = 0.001).

Conclusions: MAFLD criteria in obese children seem to be less accurate in identifying patients having an intrinsic higher cardiometabolic risk. This suggests the need for a more accurate definition in the context of pediatric obesity.

Citing Articles

Not Only Metabolic Complications of Childhood Obesity.

Ciezki S, Odyjewska E, Bossowski A, Glowinska-Olszewska B Nutrients. 2024; 16(4).

PMID: 38398863 PMC: 10892374. DOI: 10.3390/nu16040539.

The Intersection of Genetic Factors, Aberrant Nutrient Metabolism and Oxidative Stress in the Progression of Cardiometabolic Disease.

Butcko A, Putman A, Mottillo E Antioxidants (Basel). 2024; 13(1).

PMID: 38247511 PMC: 10812494. DOI: 10.3390/antiox13010087.

Kidney damage predictors in children with metabolically healthy and metabolically unhealthy obesity phenotype.

Di Sessa A, Passaro A, Colasante A, Cioffi S, Guarino S, Umano G Int J Obes (Lond). 2023; 47(12):1247-1255.

PMID: 37689826 DOI: 10.1038/s41366-023-01379-1.

Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition.

Ciardullo S, Vergani M, Ronchetti C, Perseghin G Hepatobiliary Surg Nutr. 2023; 12(4):611-615.

PMID: 37600999 PMC: 10432300. DOI: 10.21037/hbsn-23-308.

Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges.

Hegarty R, Kyrana E, Fitzpatrick E, Dhawan A Ther Adv Endocrinol Metab. 2023; 14:20420188231160388.

PMID: 36968656 PMC: 10034351. DOI: 10.1177/20420188231160388.

References

Niriella M, Ediriweera D, Kasturiratne A, De Silva S, Dassanayaka A, De Silva A . Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. PLoS One. 2021; 16(2):e0245762. PMC: 7857550. DOI: 10.1371/journal.pone.0245762. View

Castillo-Leon E, Cioffi C, Vos M . Perspectives on youth-onset nonalcoholic fatty liver disease. Endocrinol Diabetes Metab. 2020; 3(4):e00184. PMC: 7576279. DOI: 10.1002/edm2.184. View

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Hogstrom S . Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2020; 6(1):73-79. DOI: 10.1016/S2468-1253(20)30294-6. View

Di Sessa A, Cirillo G, Guarino S, Marzuillo P, Del Giudice E . Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management. Pediatric Health Med Ther. 2019; 10:89-97. PMC: 6711552. DOI: 10.2147/PHMT.S188989. View

Lin Y, Wu C, Ni Y . New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. Front Pediatr. 2020; 8:603654. PMC: 7755886. DOI: 10.3389/fped.2020.603654. View

Di Sessa A, Umano G, Del Giudice E . The Association between Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk in Children. Children (Basel). 2017; 4(7). PMC: 5532549. DOI: 10.3390/children4070057. View

Lee H, Lee Y, Kim S, Kim H . Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2020; 19(10):2138-2147.e10. DOI: 10.1016/j.cgh.2020.12.022. View

Sahota A, Shapiro W, Newton K, Kim S, Chung J, Schwimmer J . Incidence of Nonalcoholic Fatty Liver Disease in Children: 2009-2018. Pediatrics. 2020; 146(6). PMC: 7706110. DOI: 10.1542/peds.2020-0771. View

10.

Huang J, Kumar R, Wang M, Zhu Y, Lin S . MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?. J Hepatol. 2020; 73(5):1265-1267. DOI: 10.1016/j.jhep.2020.06.016. View

11.

Di Bonito P, Valerio G, Licenziati M, Miraglia Del Giudice E, Baroni M, Morandi A . High uric acid, reduced glomerular filtration rate and non-alcoholic fatty liver in young people with obesity. J Endocrinol Invest. 2019; 43(4):461-468. DOI: 10.1007/s40618-019-01130-6. View

12.

Hegarty R, Singh S, Bansal S, Fitzpatrick E, Dhawan A . NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change. J Hepatol. 2021; 74(4):991-992. DOI: 10.1016/j.jhep.2020.12.032. View

13.

Eslam M, Ratziu V, George J . Yet more evidence that MAFLD is more than a name change. J Hepatol. 2021; 74(4):977-979. DOI: 10.1016/j.jhep.2020.12.025. View

14.

Marzuillo P, Di Sessa A, Guarino S, Capalbo D, Umano G, Pedulla M . Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity. Pediatr Obes. 2019; 14(10):e12539. DOI: 10.1111/ijpo.12539. View

15.

Marzuillo P, Grandone A, Perrone L, Del Giudice E . Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease. World J Gastroenterol. 2015; 21(21):6444-50. PMC: 4458755. DOI: 10.3748/wjg.v21.i21.6444. View

16.

Morandi A, Di Sessa A, Zusi C, Umano G, El Mazloum D, Fornari E . Nonalcoholic Fatty Liver Disease and Estimated Insulin Resistance in Obese Youth: A Mendelian Randomization Analysis. J Clin Endocrinol Metab. 2020; 105(11). DOI: 10.1210/clinem/dgaa583. View

17.

Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View

18.

Targher G . Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data. Liver Int. 2020; 40(11):2879-2880. DOI: 10.1111/liv.14623. View

19.

Marzuillo P, Di Sessa A, Umano G, Nunziata L, Cirillo G, Perrone L . Novel association between the nonsynonymous A803G polymorphism of the N-acetyltransferase 2 gene and impaired glucose homeostasis in obese children and adolescents. Pediatr Diabetes. 2016; 18(6):478-484. DOI: 10.1111/pedi.12417. View

20.

Fouad Y, Elwakil R, Elsahhar M, Said E, Bazeed S, Gomaa A . The NAFLD-MAFLD debate: Eminence vs evidence. Liver Int. 2020; 41(2):255-260. DOI: 10.1111/liv.14739. View